ESH 2017 | Price vs. performance: CAR T-cells
Saar Gill
• 5 Oct 2017
The potential advantage of a therapy compared to its cost is an important factor to consider when approving novel treatments. In this video, Saar Gill, MD, PhD from the University of Pennsylvania, Philadelphia, PA, speaking from the International Conference of Acute Myeloid Leukaemia 2017, Estoril, Portugal by the European School of Hematology (ESH), talks about the resource-intensive nature of CAR T- cells and the optimal way to utilize them in the clinic in the future in regards to this.
